In a cohort of 25 patients with solid tumors, treated with IL-2 and lymphokine-activated killer cells, 11 patients had objective tumor regression, and the tumors involved were melanoma, colorectal cancer, renal cell cancer and lung adenocarcinoma [126]. The gene discussed is IL2; the disease is neoplasm.